|
1
|
Song L, Zhang S, Yu S, Ma F, Wang B, Zhang
C, Sun J, Mao X and Wei L: Cellular heterogeneity landscape in
laryngeal squamous cell carcinoma. Int J Cancer. 147:2879–2890.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdeyrim A, He S, Zhang Y, Mamtali G, Asla
A, Yusup M and Liu J: Prognostic value of lymph node ratio in
laryngeal and hypopharyngeal squamous cell carcinoma: A systematic
review and meta-analysis. J Otolaryngol Head Neck Surg. 49:312020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colevas AD, Yom SS, Pfister DG, Spencer S,
Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ,
et al: NCCN guidelines insights: Head and neck cancers, Version
1.2018. J Natl Compr Canc Netw. 16:479–490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dietz A, Wiegand S, Kuhnt T and Wichmann
G: Laryngeal preservation approaches: Considerations for new
selection criteria based on the DeLOS-II trial. Front Oncol.
9:6252019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang L, Luo D, Yi J, Li L, Zhao Y, Lin M,
Guo W, Hu L and Zhou C: Therapy effects of advanced hypopharyngeal
and laryngeal squamous cell carcinoma: Evaluated using dual-energy
CT quantitative parameters. Sci Rep. 8:90642018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang XJ, Wang W and Hann SS: Interactions
among lncRNAs, miRNAs and mRNA in colorectal cancer. Biochimie.
163:58–72. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y and Tang L: The application of
lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer
Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nandwani A, Rathore S and Datta M: lncRNAs
in cancer: Regulatory and therapeutic implications. Cancer Lett.
501:162–171. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taniue K and Akimitsu N: The functions and
unique features of lncRNAs in cancer development and tumorigenesis.
Int J Mol Sci. 22:6322021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma P, Li L, Liu F and Zhao Q:
HNF1A-induced lncRNA HCG18 facilitates gastric cancer progression
by upregulating DNAJB12 via miR-152-3p. Onco Targets Ther.
13:7641–7652. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li S, Wu T, Zhang D, Sun X and Zhang X:
The long non-coding RNA HCG18 promotes the growth and invasion of
colorectal cancer cells through sponging miR-1271 and upregulating
MTDH/Wnt/β-catenin. Clin Exp Pharmacol Physiol. 47:703–712. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li W, Pan T, Jiang W and Zhao H:
HCG18/miR-34a-5p/HMMR axis accelerates the progression of lung
adenocarcinoma. Biomed Pharmacother. 129:1102172020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Ma TT, Ma YH and Jiang YF: lncRNA
HCG18 contributes to nasopharyngeal carcinoma development by
modulating miR-140/CCND1 and Hedgehog signaling pathway. Eur Rev
Med Pharmacol Sci. 23:10387–10399. 2019.PubMed/NCBI
|
|
14
|
Testa U, Pelosi E, Castelli G and Labbaye
C: miR-146 and miR-155: Two key modulators of immune response and
tumor development. Noncoding RNA. 3:222017.PubMed/NCBI
|
|
15
|
Xu Z, Huang B, Zhang Q, He X, Wei H and
Zhang D: NOTCH1 regulates the proliferation and migration of
bladder cancer cells by cooperating with long non-coding RNA HCG18
and microRNA-34c-5p. J Cell Biochem. 120:6596–6604. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Georgantas RW, Streicher K, Greenberg SA,
Greenlees LM, Zhu W, Brohawn PZ, Higgs BW, Czapiga M, Morehouse CA,
Amato A, et al: Inhibition of myogenic microRNAs 1, 133, and 206 by
inflammatory cytokines links inflammation and muscle degeneration
in adult inflammatory myopathies. Arthritis Rheumatol.
66:1022–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv L, Li Q, Chen S, Zhang X, Tao X, Tang
X, Wang S, Che G, Yu Y and He L: miR-133b suppresses colorectal
cancer cell stemness and chemoresistance by targeting
methyltransferase DOT1L. Exp Cell Res. 385:1115972019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng W, Zhu JF, Liu JY, Li YL, Dong X,
Huang H and Shan L: miR-133b inhibits cell proliferation, migration
and invasion of esophageal squamous cell carcinoma by targeting
EGFR. Biomed Pharmacother. 111:476–484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang K, Zhou H, Yan B and Cao X:
TUG1/miR-133b/CXCR4 axis regulates cisplatin resistance in human
tongue squamous cell carcinoma. Cancer Cell Int. 20:1482020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xia L, Li S, Liu Y, Huang Y, Ni B, Wan L,
Mei H, Li X, Cai Z and Li Z: NDNF inhibits the migration and
invasion of human renal cancer cells through epithelial-mesenchymal
transition. Oncol Lett. 17:2969–2975. 2019.PubMed/NCBI
|
|
21
|
Bian Q: Circular RNA PVT1 promotes the
invasion and epithelial-mesenchymal transition of breast cancer
cells through serving as a competing endogenous RNA for miR-204-5p.
Onco Targets Ther. 12:11817–11826. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song X, Luo X, Gao Q, Wang Y, Gao Q and
Long W: Dysregulation of lncRNAs in placenta and pathogenesis of
preeclampsia. Curr Drug Targets. 18:1165–1170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou W, Ding B, Zhong G, Du C, Fan W and Fu
P: Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway
fuels stage progression of ovarian cancer. Aging (Albany NY).
11:11416–11439. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Tang X, Liu K, Hamblin MH and Yin
KJ: Long noncoding RNA malat1 regulates cerebrovascular pathologies
in ischemic stroke. J Neurosci. 37:1797–1806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mamoori A, Gopalan V and Lam AK: Role of
miR-193a in cancer: Complexity and factors control the pattern of
its expression. Curr Cancer Drug Targets. 18:618–628. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Malchers F, Ercanoglu M, Schütte D,
Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon
R, Heuckmann JM, et al: Mechanisms of primary drug resistance in
FGFR1-amplified lung cancer. Clin Cancer Res. 23:5527–5536. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haq F, Sung YN, Park I, Kayani MA, Yousuf
F, Hong SM and Ahn SM: FGFR1 expression defines clinically distinct
subtypes in pancreatic cancer. J Transl Med. 16:3742018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen S, Qiu Y, Guo P, Pu T, Feng Y and Bu
H: FGFR1 and HER1 or HER2 co-amplification in breast cancer
indicate poor prognosis. Oncol Lett. 15:8206–8214. 2018.PubMed/NCBI
|
|
29
|
Uusi-Kerttula H, Legut M, Davies J, Jones
R, Hudson E, Hanna L, Stanton RJ, Chester JD and Parker AL:
Incorporation of peptides targeting EGFR and FGFR1 into the
adenoviral fiber knob domain and their evaluation as targeted
cancer therapies. Hum Gene Ther. 26:320–329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiao J, Zhao X, Liang Y, Tang D and Pan C:
FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC)
metastasis through epithelial-mesenchymal transition (EMT). Biochem
Biophys Res Commun. 466:327–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim EK, Cho YA, Koh YW, Shin HA, Cho BC
and Yoon SO: Prognostic implications of Fibroblast growth factor
receptor 1 (FGFR1) gene amplification and protein overexpression in
hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer.
20:3482020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murugan AK: Special issue: PI3K/Akt
signaling in human cancer. Semin Cancer Biol. 59:1–2. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Narayanankutty A: PI3K/Akt/mTOR pathway as
a therapeutic target for colorectal cancer: A review of preclinical
and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khan H, Reale M, Ullah H, Sureda A, Tejada
S, Wang Y, Zhang ZJ and Xiao J: Anti-cancer effects of polyphenols
via targeting p53 signaling pathway: Updates and future directions.
Biotechnol Adv. 38:1073852020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen GY and Ruan L: Downregulation Of
microRNA-133b and its clinical value in non-small cell lung cancer.
Onco Targets Ther. 12:9421–9434. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu W, Zhan J, Zhong R, Li R, Sheng X, Xu
M, Lu Z and Zhang S: Upregulation of long noncoding RNA_GAS5
suppresses cell proliferation and metastasis in laryngeal cancer
via regulating PI3K/AKT/mTOR signaling pathway. Technol Cancer Res
Treat. 20:15330338219900742021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang B, Wu J, Guo P, Wang Y, Fang Z, Tian
J, Yu Y, Teng W, Luo Y and Li Y: Down-regulation of SREBP via
PI3K/AKT/mTOR pathway inhibits the proliferation and invasion of
non-small-cell lung cancer cells. Onco Targets Ther. 13:8951–8961.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bumbat M, Wang M, Liang W, Ye P, Sun W and
Liu B: Effects of Me2SO and trehalose on the cell viability,
proliferation, and Bcl-2 family gene (BCL-2, BAX, and BAD)
expression in cryopreserved human breast cancer cells. Biopreserv
Biobank. 18:33–40. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong B, van den Heuvel AP, Prabhu VV,
Zhang S and El-Deiry WS: Targeting tumor suppressor p53 for cancer
therapy: Strategies, challenges and opportunities. Curr Drug
Targets. 15:80–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
